Galectin targets silent epidemic in liver fibrosis
Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). Dr. Peter...
View ArticleCiclofilin developing first drug for HCV/HIV-1 co-infection
Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity...
View ArticleCiclofilin demonstrates anti-fibrotic activity with CPI-431-32
Closely-held Ciclofilin Pharmaceuticals’ lead antiviral drug has demonstrated anti-fibrotic activity in a liver fibrosis animal model. CPI-431-32 is a proprietary cyclophilin antagonist that potently...
View ArticleIn conversation with Geoffrey Hamilton-Fairley
Mr. Hamilton-Fairley As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the...
View ArticleCan-Fite gets FDA fast track for liver cancer drug
The FDA has granted Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, fast track designation as a second line treatment for hepatocellular carcinoma (HCC), the most common form of...
View ArticleHCW starts Galectin Therapeutics at buy
H.C. Wainwright has initiated coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and 12-month price target of $7. The stock closed at $2.28 on Friday. Galectin is a clinical-stage...
View ArticleLeerink starts Tobira Therapeutics at outperform
Leerink Partners has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with an “outperform” rating and $24 price target in 12 months. The stock closed at $9.26 on Thursday. Tobira is aiming to...
View ArticleCan-Fite expands development of CF102 into NASH
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded...
View ArticleHCW starts Tobira Therapeutics at buy
H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday. Tobira is focused on the development of a sole...
View ArticleGalectin completes patient recruitment in NASH trial
Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX...
View Article
More Pages to Explore .....